Abstract

Irritable bowel syndrome (IBS) is one of the most commonly diagnosed gastrointestinal conditions. It represents a significant healthcare burden and remains a clinical challenge. Over the years IBS has been described from a variety of different perspectives; from a strict illness of the gastrointestinal tract (medical model) to a more complex multi-symptomatic disorder of the brain-gut axis (biopsychosocial/ psychosomatic model).1 In this article we present aspects of the pathophysiology and the non-pharmacological treatment of IBS based on current knowledge. Effects of conditioned stress and/or traumatic influences on the emotional system (topdown) as well as effects on the intestine through stressors, infection, inflammation, food and dysbiosis (bottom-up) can affect brain-gut communication and result in dysregulation of the autonomic nervous system (ANS), playing an important role in the pathophysiology of IBS. Conditioned stress together with dysregulation of the autonomic nervous system and the emotional system may involve reactions in which the distress inside the body is not recognized due to low body awareness.2 This may explain why patients have difficulty identifying their symptoms despite dysfunction in muscle tension, movement patterns, and posture and biochemical functions in addition to gastrointestinal symptoms. IBS shares many features with other idiopathic conditions, such as fibromyalgia, chronic fatigue syndrome, and somatoform disorders. The key to effective treatment is a thorough examination, including a gastroenterological examination to exclude other diseases along with an assessment of body awareness by a body-mind therapist. The literature suggests that early interdisciplinary diagnostic co-operation between gastroenterologists and body-mind therapists is necessary.3 Re-establishing balance in the ANS is an important component of IBS treatment. This article discusses the current knowledge of body-mind treatment, addressing the topic from a practical point of view.

• 1.   Ford A.C., Talley N.J. Irritable bowel syndrome. BMJ. 2012; 345: e5836. doi: 10.1136/bmj.e5836.
• 2.   Vol U., Lewerenz A., Nieber K. Treatment of irritable bowel syndrome: Sex and gender specific aspects. Handb Exp Pharmacol. 2012; (214): 473–497. doi: 10.1007/978-3-642-30726-
• 4.   Boeckxstaens G., Corazziari E.S., Mearin F., Tack J. IBS and the role of otilonium bromide. Int J Colorectal Dis. 2013;28:295–304. doi: 10.1007/s00384-012-1598-0.
• 5.   Spiller R., Aziz Q., Creed F., Emmanuel A., Houghton L., Hungin P., Jones R., Kumar D., Rubin G., Trudgill N., et al. Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut. 2007; 56: 1770– 1798. doi: 10.1136/gut.2007.119446.
• 6.   Sandler R.S., Everhart J.E., Donowitz M., Adams E., Cronin K., Goodman C., Gemmen E., Shah S., Avdic A., Rubin R. The burden of selected digestive diseases in the United States. Gastroenterology. 2002; 122: 1500–1511. doi: 10.1053/gast.2002.32978.
• 7.   Inadomi J.M., Fennerty M.B., Bjorkman D. Systematic review: the economic impact of irritable bowel syndrome. Aliment Pharmacol Ther. 2003; 18: 671–682. doi: 10.1046/j.1365- 2036.2003.t01-1-01736.x.
• 8.   Hillilä M.T., Färkkilä N.J., Färkkilä M.A. Societal costs for irritable bowel syndrome- -a population based study. Scand J Gastroenterol. 2010; 45: 582–591. doi: 10.3109/00365521003637211.
• 9.   Heitkemper M., Jarrett M., Jun S.E. Update on irritable bowel syndrome program of research. J Korean Acad Nurs. 2013; 43: 579–586. doi: 10.4040/jkan.2013.43.5.579.
• 10.   Longstreth G.F., Yao J.F. Irritable bowel syndrome and surgery: a multivariable analysis. Gastroenterology. 2004; 126: 1665– 1673. doi: 10.1053/j.gastro.2004.02.020.
• 11.   Lembo A., Ameen V.Z., Drossman D.A. Irritable bowel syndrome: toward an understanding of severity. Clin Gastroenterol Hepatol. 2005; 3: 717–725. doi: 10.1016/s1542-3565(05)00157-6.
• 12.   Spiegel B., Schoenfeld P., Naliboff B. Systematic review: The prevalence of suicidal behaviour in patients with chronic abdominal pain and irritable bowel syndrome. Aliment Pharmacol Ther. 2007; 26: 183–193. doi: 10.1111/j.1365- 2036.2007.03357.x.
• 13.   Mönnikes H. Quality of life in patients with irritable bowel syndrome. J Clin Gastroenterol. 2011; 45 Suppl: S98–101. doi: 10.1097/ MCG.0b013e31821fbf44.
• 14.   Chang J.Y., Talley N.J. An update on irritable bowel syndrome: from diagnosis to emerging therapies. Curr Opin Gastroenterol. 2011; 27: 72–78. doi: 10.1097/MOG.0b013e3283414065.
• 15.   Henderson P.K., DiPalma J.A. Diagnosing irritable bowel syndrome: a changing clinical paradigm. South Med J. 2011; 104: 195–199. doi: 10.1097/SMJ.0b013e31820bfb6c.

Data Sharing Statement

Funding